Search
technetium 99mTc fanolesomab (Neutrospec)
Tradename: Neutrospec 2005: Marketing suspended for evaluation of immediate & life-threatening hypersensitivity reactions. [3]
Indications:
- radiopharmaceutical used in scintigraphy
Adverse effects:
- cardiopulmonary failure (hypersensitivity reaction)
- hypoxia, dyspnea, hypotension, cardiac arrest
- generally occurs within 30 minutes of administration
Mechanism of action:
- radiopharmaceutical
Notes: Manufacturer: Palatin
General
radiopharmaceutical
References
- Prescriber's Letter 12(2): 2005
New Drugs Approved by the FDA in 2004
Detail-Document#: 210216
(subscription needed) http://www.prescribersletter.com
- FDA MedWatch
http://www.fda.gov/medwatch/safety/2005/safety05.htm#NeutroSpec
- Prescriber's Letter 13(2): 2006
Detail-Document#: 220215
(subscription needed) http://www.prescribersletter.com